journal article·2026-03Open access

Biomimetic Iridium‐Based Photothermal Nanozyme to Trigger Ferroptosis and Pyroptosis and Activate the cGAS‐STING Pathway for Improved Tumor Immunotherapy

Lijun Ding, Zhongxiong Fan, Guoyu Xia, Fukai Zhu, Nan Yang, Shujie Yu, Longlong Yuan, Jinyao Li

Advanced Science· Volume 13· Issue 16

Abstract

ABSTRACT Although nanozymes are potential tumor therapeutics due to their ability to disrupt intracellular redox homeostasis, developing nanozymes with higher therapeutic efficacy and clarifying their antitumor mechanism are challenging. Here, an iridium (Ir)‐based nanozyme (IIN) was constructed through coordination‐driven co‐assembly using photosensitizer indocyanine green (ICG), Ir, and indoleamine 2,3‐dioxygenase (IDO) inhibitor NLG8189. Then, the IIN was mimicked by tumor cell lysate (TCL)‐simulated dendritic cell (DC) membrane to form IIN@M. Based on superior enzyme‐like activity and photothermal performance, IIN@M disrupted the intracellular redox homeostasis by generating reactive oxygen species (ROS) and depleting glutathione (GSH). GSH depletion induced ferroptosis, and ROS burst under photothermal irradiation triggered pyroptosis, thus synergistically enhancing immunogenic cell death (ICD). The generated ROS could promote mitochondrial DNA (mtDNA) oxidative damage and release, finally activating the immune response by the cyclic GMP‐AMP synthase‐simulator of interferon gene (cGAS‐STING) pathway. In vivo experiments also suggested that IIN@M could efficiently ablate the primary tumor, especially under photothermal irradiation. Furthermore, it could suppress distant tumor progression by triggering the immune response, especially under photothermal irradiation, which was accompanied by increased DC maturation, M1 macrophage polarization, and T cell infiltration in tumor tissue. This study proposed a promising strategy for effective Ir‐based nanozyme in tumor immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · interferon and immune responses · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Sciences Institute of Materia Medica Xinjiang University Urumqi China

Xinjiang Key Laboratory of Biological Resources and Genetic Engineering College of Life Science and Technology Xinjiang University Urumqi China

Funding

National Natural Science Foundation of China

References (64)

Show source-provided references
1. Endogenous/Exogenous Dual‐responsive Nanozyme for Photothermally Enhanced Ferroptosis‐immune Reciprocal Synergistic Tumor Therapy
2. 10.1016/j.pharmthera.2020.10775310.1016/j.pharmthera.2020.107753 ↗
3. 10.1021/acsnano.4c1728510.1021/acsnano.4c17285 ↗
4. Nanozyme‐Based Strategies in Cancer Immunotherapy: Overcoming Resistance to Enhance Therapeutic Efficacy
5. 10.1002/adfm.20230249310.1002/adfm.202302493 ↗
6. 10.1002/adfm.20240157610.1002/adfm.202401576 ↗
7. 10.1021/acsnano.4c0785110.1021/acsnano.4c07851 ↗
8. 10.1002/adma.20250033710.1002/adma.202500337 ↗
9. 10.1016/j.biomaterials.2024.12274510.1016/j.biomaterials.2024.122745 ↗
10. Chiral Ruthenium Nanozymes with Self‐Cascade Reaction Driven the NO Generation Induced Macrophage M1 Polarization Realizing the Lung Cancer
11. 10.1038/s41467-025-57190-110.1038/s41467-025-57190-1 ↗
12. 10.1002/adma.20221003710.1002/adma.202210037 ↗
13. 10.1021/acsami.4c1388910.1021/acsami.4c13889 ↗
14. 10.1002/adma.20250634910.1002/adma.202506349 ↗
15. 10.1021/acsnano.4c0737410.1021/acsnano.4c07374 ↗
16. 10.1016/j.mtbio.2025.10223010.1016/j.mtbio.2025.102230 ↗
17. 10.1016/j.actbio.2023.10.01810.1016/j.actbio.2023.10.018 ↗
18. 10.1002/adfm.20250443410.1002/adfm.202504434 ↗
19. 10.1002/EXP.2022001410.1002/EXP.20220014 ↗
20. 10.1002/EXP.2022016110.1002/EXP.20220161 ↗
21. 10.1016/j.jconrel.2023.04.03010.1016/j.jconrel.2023.04.030 ↗
22. 10.1016/j.biomaterials.2025.12343410.1016/j.biomaterials.2025.123434 ↗
23. 10.1016/j.nantod.2025.10287610.1016/j.nantod.2025.102876 ↗
24. 10.1186/s12951-025-03608-310.1186/s12951-025-03608-3 ↗
25. Polymer‐PARPi Conjugates Delivering USP1i for Maximizing Synthetic Lethality to Stimulate STING Pathway in High‐Grade Serous Ovarian Cancer
26. 10.1038/s41467-020-15730-x10.1038/s41467-020-15730-x ↗
27. 10.1002/ange.20211292510.1002/ange.202112925 ↗
28. 10.1021/jacs.4c1515010.1021/jacs.4c15150 ↗
29. 10.1021/acsnano.4c1890410.1021/acsnano.4c18904 ↗
30. 10.1186/s12951-025-03255-810.1186/s12951-025-03255-8 ↗
31. 10.1186/s12951-024-02913-710.1186/s12951-024-02913-7 ↗
32. 10.1016/j.bioactmat.2021.12.02010.1016/j.bioactmat.2021.12.020 ↗
33. 10.1002/adfm.20220634610.1002/adfm.202206346 ↗
34. 10.1021/acsnano.4c1890410.1021/acsnano.4c18904 ↗
35. Synergistic Copper‐Coordination/Glutathione Reduction Drives an in Situ Type II‐to‐Type I Photodynamic Switch in Iridium‐Based Photosensitizer Nanocomposites for Potentiated Cancer Immunotherapy
36. 10.1021/acsami.5b0127110.1021/acsami.5b01271 ↗
37. Indocyanine Green‐Conjugated Magnetic Prussian Blue Nanoparticles for Synchronous Photothermal/Photodynamic Tumor Therapy
38. 10.1186/s13045-025-01684-410.1186/s13045-025-01684-4 ↗
39. 10.1002/anie.20230556410.1002/anie.202305564 ↗
40. A Cyanine With 83.2% Photothermal Conversion Efficiency and Absorption Wavelengths Over 1200 Nm for Photothermal Therapy
41. 10.1002/agt2.70610.1002/agt2.706 ↗
42. 10.1021/jacs.9b1180010.1021/jacs.9b11800 ↗
43. Enhanced Stability and Photothermal Efficiency of Indocyanine Green J‐aggregates by Nanoformulation With Calix 4 Arene for Photothermal Therapy of Cancers
44. 10.1039/D2NR06058B10.1039/D2NR06058B ↗
45. 10.1002/anie.20201591310.1002/anie.202015913 ↗
46. Enhancing Catalase‐Like Activity of Prussian Blue Nanozyme by Gadolinium‐doping for Imaging‐guided Antitumor Amplification via Photodynamic Therapy and Chemotherapy
47. 10.1021/acs.analchem.2c0040010.1021/acs.analchem.2c00400 ↗
48. Cancer Immunogenic Cell Death via Photo‐pyroptosis With Light‐sensitive Indoleamine 2,3‐dioxygenase Inhibitor Conjugate
49. 10.1021/acs.nanolett.3c0100810.1021/acs.nanolett.3c01008 ↗
50. 10.1002/smll.20220216110.1002/smll.202202161 ↗
51. 10.1002/smll.20240815610.1002/smll.202408156 ↗
52. HIF‐1a Drives Resistance to Ferroptosis in Solid Tumors by Promoting Lactate Prodtion and Activating SLC1A1
53. 10.1021/jacs.4c0830410.1021/jacs.4c08304 ↗
54. 10.1016/j.bpj.2014.11.02910.1016/j.bpj.2014.11.029 ↗
55. Triple‐pathway cGAS‐STING Activation Collaborated With Ferroptosis‐induced Immunogenic Cell Death for Boosting Systemic Colorectal Cancer Immunotherapy
56. 10.1021/acsami.1c2280410.1021/acsami.1c22804 ↗
57. 10.1016/j.biomaterials.2024.12251210.1016/j.biomaterials.2024.122512 ↗
58. 10.1021/acsnano.4c0861310.1021/acsnano.4c08613 ↗
59. 10.1016/j.immuni.2021.10.02010.1016/j.immuni.2021.10.020 ↗
60. 10.1038/s41556-023-01343-110.1038/s41556-023-01343-1 ↗
61. 10.1002/advs.20250235610.1002/advs.202502356 ↗
62. 10.1016/j.biomaterials.2023.12233310.1016/j.biomaterials.2023.122333 ↗
63. 10.1016/j.molcel.2022.02.00710.1016/j.molcel.2022.02.007 ↗
64. 10.1021/acsnano.2c0903310.1021/acsnano.2c09033 ↗